A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.

开始日期2024-10-12

申办/合作机构

北京科兴中维生物技术有限公司

100 项与 13价肺炎球菌结合疫苗(北京科兴中维) 相关的临床结果

登录后查看更多信息

100 项与 13价肺炎球菌结合疫苗(北京科兴中维) 相关的转化医学

登录后查看更多信息

100 项与 13价肺炎球菌结合疫苗(北京科兴中维) 相关的专利（医药）

登录后查看更多信息

项与 13价肺炎球菌结合疫苗(北京科兴中维) 相关的文献（医药）

2023-02-16·Antimicrobial Agents and Chemotherapy

Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan

Article

作者: Nakano, Satoshi ; Ito, Yutaka ; Suga, Shigeru ; Chang, Bin ; Matsumura, Yasufumi ; Shinohara, Koh ; Sugai, Motoyuki ; Ohnishi, Makoto ; Yamamoto, Masaki ; Fujisawa, Takao ; Nagao, Miki

2021-06-03·Expert Review of Vaccines2区 · 医学

Vaccination coverage among health-care workers: pre–post intervention study to assess impact of an on-site vaccination-dedicated clinic

2区 · 医学

Article

作者: Cautela, Vincenza ; Nobile, Carmelo Giuseppe Angelo ; Pileggi, Claudia ; De Sarro, Caterina ; Pavia, Maria ; Papadopoli, Rosa

BACKGROUNDSeveral studies have revealed low vaccinations coverage among health-care workers (HCWs) for all vaccinations. The aim of our study was to evaluate the impact of the implementation of an on-site vaccination-dedicated clinic on the vaccination coverage rates of HCWs.RESEARCH DESIGN AND METHODSA quasi-experimental pre-post intervention study was carried out among undergraduate and postgraduate students attending medical and health-care professions schools.RESULTSWe enrolled 804 students, 404 in the control and 400 in the experimental group. A significantly higher increase of vaccination coverage in the experimental group than in the control group for all the investigated vaccinations (p < 0.001) was found. The odds of adherence to vaccinations in the experimental group, compared to the control group, ranged from 6.9-fold (95% CI 3.51-13.44) to 18.9-fold (95% CI 10.85-32.96). The increase in the coverage rate in the control group was between 2.5% and 3.5%, whereas in the experimental group, higher increases were found, ranging from 34.8% to 71%.CONCLUSIONSThe extraordinary increase in the adherence to HCWs recommended vaccinations found in the study seems to indicate a significant role of enabling factors in the complex process of decision-making and implementation of health-related behaviors.

100 项与 13价肺炎球菌结合疫苗(北京科兴中维) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺炎球菌感染	临床3期	-	北京科兴中维生物技术有限公司	2024-10-12
肺炎	临床前	中国	北京科兴生物制品有限公司	2018-04-10
肺炎	临床前	中国	北京科兴中维生物技术有限公司	2018-04-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Pediatr Infect Dis J	N/A	肺炎球菌感染 \| HIV感染	-	13-Valent Pneumococcal Conjugate Vaccine (Children with HIV)	窪淵糧夢鏇膚襯選窪選(簾淵糧顧夢鏇遞觸憲繭) = 製獵蓋鑰願製鏇衊夢憲艱鏇範築襯鹽鏇獵選鏇 (蓋鏇願膚鑰簾築顧糧衊 ) 更多	-	2018-05-01
				13-Valent Pneumococcal Conjugate Vaccine (HIV-uninfected children)	窪淵糧夢鏇膚襯選窪選(簾淵糧顧夢鏇遞觸憲繭) = 齋顧艱憲窪製簾築鏇衊艱鏇範築襯鹽鏇獵選鏇 (蓋鏇願膚鑰簾築顧糧衊 ) 更多
Pubmed \| Pediatr Infect Dis J	N/A	-	284	13-valent pneumococcal conjugate vaccine (Children between 15 months and 2 years of age)	壓構糧廠鏇夢積範淵廠(襯醖憲顧簾積鬱壓齋蓋) = 構遞範願鏇觸簾積網壓範齋醖醖願壓鹹襯積觸 (襯顧觸遞醖糧夢衊襯簾 )	-	2011-12-01
				13-valent pneumococcal conjugate vaccine (Children between 2 and 5 years)	壓構糧廠鏇夢積範淵廠(襯醖憲顧簾積鬱壓齋蓋) = 艱夢膚積襯遞鬱窪壓構範齋醖醖願壓鹹襯積觸 (襯顧觸遞醖糧夢衊襯簾 )